argenx - Another CSS beat but ADDRESS readout expected to be top of mind among investors
*This morning, ARGX released Q3 results, most notably announcing 1/ another VYVGART CSS sales beat (USD 239m vs. USD 295m BB CSS) and 2/ filing of the VYVGART Hytrulo sBLA for CIDP by year-end with intention to use the priority review voucher (PRV) expected to result in approval in 2024.*Clinical and commercial timelines mostly reiterated or moved up: readouts of pivotal ADDRESS (Pemphigus) and ADVANCE-SC (ITP) studies expected around year-end. *We stick to our TP and Buy rating in light of the imminent ADDRESS and ADVANCE-SC readouts. Especially the former is top of mind among investors as a successful readout wouldArgenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.